Category: Federal Forum Posters
Purpose: The incidence of statin-induced myalgia/myopathy in the literature is low compared to providers’ perception of the incidence observed in practice at a veterans affairs medical center. Large-scale evidence from randomized trials show about 10-20 cases annually per 10,000 treated patients. Providers have difficulty determining the best approach for managing patients at high cardiovascular disease risk who report statin intolerance. The purpose of this study is to determine the incidence of documented adverse drug events of myopathy/myalgia to statins at our institution and determine what course of action was taken for hyperlipidemic control when the adverse drug event was observed.
Methods: This study will be submitted to the Institutional Review Board for approval. Patients over the age of 18 that have a documented adverse drug event of myalgia/myopathy to statin medications will be identified from the electronic medical record. A random sample size will be taken from that cohort of patients and will be included in the retrospective chart review. Individuals with an adverse event will be evaluated on the following: historical vs observed, liver function tests and creatinine kinase levels, adverse drug events to multiple statins and/or other antihyperlipidemic agents, current statin and/or other antihyperlipidemic therapy, outcome of adverse drug event (i.e. medication discontinued, dose lowered, etc.), and determination of statin benefit group. All data will be recorded in an excel document without patient identifiers and maintained confidentially. Descriptive statistics will be compiled and reported.
Results: not applicable
Conclusion: not applicable
Lindsay Scheffel– Pharmacy Resident, Louis A Johnson Veterans Affairs Medical Center, Morgantown, WV